Systemic Mastocytosis - Pipeline Review, H1 2015

Published: Jun, 2015 | Pages: 79 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Systemic Mastocytosis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Systemic Mastocytosis - Pipeline Review, H1 2015', provides an overview of the Systemic Mastocytosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Systemic Mastocytosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Mastocytosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Systemic Mastocytosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Systemic Mastocytosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Systemic Mastocytosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Systemic Mastocytosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Systemic Mastocytosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Systemic Mastocytosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Systemic Mastocytosis Overview 6
Therapeutics Development 7
Pipeline Products for Systemic Mastocytosis - Overview 7
Pipeline Products for Systemic Mastocytosis - Comparative Analysis 8
Systemic Mastocytosis - Therapeutics under Development by Companies 9
Systemic Mastocytosis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Systemic Mastocytosis - Products under Development by Companies 13
Systemic Mastocytosis - Companies Involved in Therapeutics Development 14
AB Science 14
Blueprint Medicines 15
Bristol-Myers Squibb Company 16
Novartis AG 17
Patara Pharma, Inc. 18
Pharmacyclics, Inc. 19
Stemline Therapeutics, Inc. 20
Systemic Mastocytosis - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
BLU-285 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
cromolyn sodium - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
dasatinib - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ibrutinib - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
masitinib - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
midostaurin - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
SL-401 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Systemic Mastocytosis - Recent Pipeline Updates 49
Systemic Mastocytosis - Discontinued Products 76
Systemic Mastocytosis - Product Development Milestones 77
Featured News & Press Releases 77
Dec 08, 2014: Blueprint Medicines Debuts Comprehensive Preclinical Data Set on First Selective Drug for Patients with Systemic Mastocytosis at 2014 American Society of Hematology Annual Meeting 77
Appendix 78
Methodology 78
Coverage 78
Secondary Research 78
Primary Research 78
Expert Panel Validation 78
Contact Us 78
Disclaimer 79

List of Tables

Number of Products under Development for Systemic Mastocytosis, H1 2015 7
Number of Products under Development for Systemic Mastocytosis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Systemic Mastocytosis - Pipeline by AB Science, H1 2015 14
Systemic Mastocytosis - Pipeline by Blueprint Medicines, H1 2015 15
Systemic Mastocytosis - Pipeline by Bristol-Myers Squibb Company, H1 2015 16
Systemic Mastocytosis - Pipeline by Novartis AG, H1 2015 17
Systemic Mastocytosis - Pipeline by Patara Pharma, Inc., H1 2015 18
Systemic Mastocytosis - Pipeline by Pharmacyclics, Inc., H1 2015 19
Systemic Mastocytosis - Pipeline by Stemline Therapeutics, Inc., H1 2015 20
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Stage and Target, H1 2015 23
Number of Products by Stage and Mechanism of Action, H1 2015 25
Number of Products by Stage and Route of Administration, H1 2015 27
Number of Products by Stage and Molecule Type, H1 2015 29
Systemic Mastocytosis Therapeutics - Recent Pipeline Updates, H1 2015 49
Systemic Mastocytosis - Discontinued Products, H1 2015 76